A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Menin, BTK and a Car-T skirmish featured over the ASH weekend.
The company impresses investors, but money’s running short.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
